In a current study, Dr. Marina Scheller (now at the University Hospital Hamburg-Eppendorf) and Professor Achim Leutz report that these two processes in CML – disease progression and drug resistance – are directly associated with each other due to crosstalk between two cellular signaling pathways.
Their findings may lead to new strategies for developing combination treatments to halt the progression of the disease (Journal of Experimental Medicine, doi:10.1084/jem.20130706)*.
In CML, the white blood cells (leukocytes) multiply in an uncontrolled fashion. This is caused by a mutation in the DNA of a single blood stem cell. In this mutation, parts of chromosome 9 fuse with parts of chromosome 22. This discovery was made in 1960 and termed the “Philadelphia chromosome” after the place it was discovered in the U.S. The product of the Philadelphia chromosome is the BCR-ABL oncogene. The protein product of this BCR-ABL gene is a tyrosine kinase which is responsible for the excessive proliferation of the white blood cells and for triggering the progression of chronic myeloid leukemia.
About 15 years ago a novel drug (imatinib) was developed that can block the tyrosine kinase produced by the Philadelphia chromosome. With imatinib, which has been used since 2001, the disease can be suppressed in the majority of CML patients.
However, with increasing duration of the disease, leukemia cells can develop resistance to imatinib, and the drug treatment can lose its effectiveness in some of the patients. A consequence is the emergence of the so-called blast crisis in which the blood of the patients is flooded with immature white blood cells (blasts). This phase is life-threatening because drug treatment is usually unsuccessful. Many CML experts attribute the disease progression to changes in the so-called “leukemia stem cells”. Thus, to prevent disease relapse, researchers across the globe are seeking to decipher the disease mechanisms and to develop new treatment options to eliminate these highly malignant leukemia stem cells.Two signaling pathways under scrutiny
The cancer researchers also focused on the interferon signaling pathway, and particularly on the function of the interferon regulatory factor 8 (Irf8). Irf8 protects against infection and regulates the production of a specific type of white blood cells, the granulocytes. It is also known that Irf8 counteracts the BCR-ABL oncoprotein and may suppress the development of cancer.Direct association
“The Philadelphia chromosome inhibits the tumor suppressor Ifr8. The suppression of Irf8 activity promotes the development of CML. But the suppression of Irf8 alone is not sufficient to trigger a blast crisis,” said Professor Leutz. “What is crucial is the activity of the beta-catenin protein. Beta-catenin is the amplifier of the misguided cell differentiation and cell division. Beta-catenin activation speeds up the uncontrolled growth of the white blood cells and prevents their maturation into functional granulocytes,” he added.
“We were able to demonstrate that the loss of the interferon regulatory factor 8 (Irf8) and the subsequent activation of the Wnt/beta-catenin signaling pathway lead to an aggressive behavior of the CML stem cell with the BCR-ABL gene,” the authors of the study summarized their findings. According to the cancer researchers, precisely these two changes in the leukemia stem cell, suppression of Ifr8 and activation of beta-catenin, are part of the fact that imatinib and related drugs lose their effectiveness and help the leukemia stem cells to survive.
Professor Leutz also pointed out that before the drug imatinib existed, CML was also treated with interferon-alpha (IFN-alpha). Interferon-alpha induces an increase in Ifr8 proteins and simultaneously an improved response to imatinib. “When there is a relapse,” he said, “it may be advantageous to additionally increase Irf8 and to suppress the deregulated beta-catenin.” In the laboratory, Professor Leutz and his team have already achieved this objective in mice.*Crosstalk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance
4Institute of Molecular Tumor Biology - IMTB, Medical Faculty of the University of Muenster, Robert-Koch-Str. 43, 48149, Münster, Germany.Contact:
Barbara Bachtler | Max-Delbrück-Centrum
Further reports about: > CML > Cancer treatment > Drug Delivery > MDC > Medicine > Molecular Target > Parkinson’s Disease > blood cell > cancer research > chronic insomnia > drug treatment > leukemia > myeloid > regulatory factor > signaling pathway > stem cells > tumor suppressor > white blood cell
World first: Massive thrombosis removed during early pregnancy
20.07.2017 | Universitätsspital Bern
Therapy of preterm birth in sight?
19.07.2017 | Universitätsspital Bern
Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.
For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...
What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.
To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...
The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....
A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...
Physics supports biology: Researchers from PTB have developed a model system to investigate friction phenomena with atomic precision
Friction: what you want from car brakes, otherwise rather a nuisance. In any case, it is useful to know as precisely as possible how friction phenomena arise –...
19.07.2017 | Event News
12.07.2017 | Event News
12.07.2017 | Event News
20.07.2017 | Information Technology
20.07.2017 | Materials Sciences
20.07.2017 | Physics and Astronomy